738 related articles for article (PubMed ID: 22532316)
41. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
[TBL] [Abstract][Full Text] [Related]
42. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.
Onor IO; Todd SB; Meredith E; Perez SD; Mehta AK; Marshall Lyon G; Knechtle SJ; Hanish SI
Transpl Int; 2013 Jun; 26(6):592-600. PubMed ID: 23590709
[TBL] [Abstract][Full Text] [Related]
44. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
45. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
[TBL] [Abstract][Full Text] [Related]
46. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
47. Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients.
Limaye AP; La Rosa C; Longmate J; Diamond DJ
Transplantation; 2016 Jan; 100(1):210-6. PubMed ID: 26680375
[TBL] [Abstract][Full Text] [Related]
48. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
49. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Brady RL; Green K; Frei C; Maxwell P
Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
[TBL] [Abstract][Full Text] [Related]
50. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
51. Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching.
Kim SI; Kim CJ; Kim YJ; Son H; Kim YE; Kim MS; Hwang S; Kim JI; You YK; Kim DG; Kang MW
Transplant Proc; 2012 Apr; 44(3):787-90. PubMed ID: 22483496
[TBL] [Abstract][Full Text] [Related]
52. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
[TBL] [Abstract][Full Text] [Related]
53. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.
Kijpittayarit-Arthurs S; Eid AJ; Kremers WK; Pedersen RA; Dierkhising RA; Patel R; Razonable RR
J Heart Lung Transplant; 2007 Oct; 26(10):1019-24. PubMed ID: 17919622
[TBL] [Abstract][Full Text] [Related]
54. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.
Mendez-Eirin E; Paniagua-Martín MJ; Marzoa-Rivas R; Barge-Caballero E; Grille-Cancela Z; Cañizares A; Naya-Leira C; Gargallo-Fernández P; Castro-Beiras A; Crespo-Leiro M
Transplant Proc; 2012 Nov; 44(9):2660-2. PubMed ID: 23146486
[TBL] [Abstract][Full Text] [Related]
55. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
56. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
57. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
59. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
Díaz-Pedroche C; Lumbreras C; San Juan R; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno-Elola A; Hernando S; Moreno-González E; Aguado JM
Transplantation; 2006 Jul; 82(1):30-5. PubMed ID: 16861938
[TBL] [Abstract][Full Text] [Related]
60. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
